Polymorphous light eruption
Methodology & AI Transparency ⓘ
Polymorphous light eruption Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Polymorphous light eruption (L56.4; Dermatology: Acne, Eczema, Psoriasis & Rosacea) utilize dermoscopy or punch in Polymorphous light eruption (L56.4: biopsy when atypical) and objective Fasting Lipids & in Polymorphous light eruption (L56.4: ALT (if systemic) targets (Within baseline reference limits (L56.4)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Federal ICD-10-CM code L56.4 categorizes Polymorphous light eruption under Dermatology: Acne, Eczema, Psoriasis & Rosacea.
- 3 Typical cash cost range: Primary evaluation for Polymorphous light eruption incorporates dermoscopy or punch in Polymorphous light eruption (L56.4: biopsy when atypical) and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Polymorphous light eruption monitoring tracks Fasting Lipids & in Polymorphous light eruption (L56.4: ALT (if systemic) toward Within baseline reference limits (L56.4).
Ask our AI Specialists anything about Polymorphous light eruption
What Is Polymorphous light eruption?
Physicians managing Polymorphous light eruption (L56.4; Dermatology: Acne, Eczema, Psoriasis & Rosacea) utilize dermoscopy or punch in Polymorphous light eruption (L56.4: biopsy when atypical) and objective Fasting Lipids & in Polymorphous light eruption (L56.4: ALT (if systemic) targets (Within baseline reference limits (L56.4)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Polymorphous light eruption (L56.4) center on or pilosebaceous follicular in Polymorphous light eruption (L56.4: hyperkeratinization). targeted skin & dermatology interventions aim to normalize Fasting Lipids & in Polymorphous light eruption (L56.4: ALT (if systemic).
Common Symptoms & Clinical Signs
- • Presentation of Polymorphous light eruption (L56.4): persistent erythematous plaques, in Polymorphous light eruption (L56.4: scaly patches, pruritic)
- • Secondary Polymorphous light eruption clinical sign: compromised epidermal barrier in Polymorphous light eruption (L56.4: with dryness, fissuring,)
- • Symptom flares in Polymorphous light eruption correlating with Fasting Lipids & in Polymorphous light eruption (L56.4: ALT (if systemic) deviation outside Within baseline reference limits (L56.4)
- • Functional skin & dermatology impact requiring dermoscopy or punch in Polymorphous light eruption (L56.4: biopsy when atypical) evaluation (L56.4)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Polymorphous light eruption Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L56.4 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Fasting Lipids & in Polymorphous light eruption (L56.4: ALT (if systemic) | Within baseline reference limits (L56.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Polymorphous light eruption (L56.4: & hs-CRP) | 25(OH)D 40–65 ng/mL (L56.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Polymorphous light eruption (L56.4: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L56.4) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Polymorphous light eruption
Treatment selection for Polymorphous light eruption depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Polymorphous light eruption)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Secukinumab maintains superiority over ustekinumab in clearing skin and improving: What a 550-Participant Study Found This second head-to-head study confirmed the superior efficacy of secukinumab over ustekinumab in skin clearance and quality of life through 52 weeks, with safety comparable to that reported in previous trials. Journal of the European Academy of Dermatology and Venereology : JEADV • 2021-01-15 • Phase III Randomized Trial | N = 550 | 93/100 | PMID 32365251 ↗ |
| New Insights on Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in: What a 413-Participant Study Found Objective and subjective measures of efficacy supported the evaluation of biosimilarity between AVT02 and originator adalimumab at Week 16 and until Week 50, in switched and continued treatment groups. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy • 2021-11-15 • Phase III Randomized Trial | N = 413 | 93/100 | PMID 34657274 ↗ |
| Can This Approach Help? Inside the Latest Research on Treatment of severe cystic acne with 13-cis-retinoic acid. Evaluation of sebum The most common clinical side effects were cheilitis, desquamation of the skin, and severe itching, but the side effects were not severe enough to require interruption of treatment. Journal of the American Academy of Dermatology • 1980-12-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 6451637 ↗ |
| What the Latest Evidence Really Says About Comorbidities Associated With Lichen LPP is significantly associated with autoimmune disorders, thyroid diseases, and skin cancer. International journal of dermatology • 2025-12-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 40579650 ↗ |
| What the Latest Evidence Really Says About Eczema: global epidemiology and risk AD has been described as an allergic skin disease, but today, the contribution of allergic reactions to the initiation of AD is challenged, and it is proposed that allergy is rather a consequence of AD in subjects with a... Annals of nutrition & metabolism • 2015-01-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 25925336 ↗ |
Polymorphous light eruption Patient Community & “People Like Me” Threads
Filter Polymorphous light eruption community threads and patient logs by age, biological sex, dosage, and treatment duration.